These new findings from BRAVE-AA trials show most adult and adolescent responders to baricitinib treatment achieved full scalp hair regrowth, with significant improvements seen as early as Week 8.

The POSITIVE study demonstrates that tildrakizumab provides sustained relief from psoriasis skin symptoms while enhancing psychological well-being and partner quality of life, highlighting its role as an important option in holistic management of psoriatic disease.

This study highlights key baseline risk factors, including BMI ≥30 and PEST score 2, that predict progression from psoriasis to PsA over 24 months. It explores the impact of biologic treatments on risk reduction, offering insights for dermatologists and rheumatologists.

Discover the long-term benefits of tildrakizumab for chronic plaque psoriasis. This study reports final results from the reSURFACE 1 and 2 extension studies, revealing sustained efficacy, robust safety, and minimal immunogenicity over 368 weeks. With PASI 75/90/100 responses maintained in most patients, tildrakizumab offers a promising treatment option for lasting relief.

This study introduces an SPF50+ sunscreen designed for actinic keratosis patients. It demonstrated excellent skin tolerance and acceptability, as well as 94.4% protection against UV-induced DNA lesions, lipidome stabilisation, and compatibility with MAL-dPDT.

Discover real-world insights into actinic keratosis management from a specialised cancer center. This study highlights patient and lesion characteristics influencing treatment outcomes, adherence to follow-up, and the effectiveness of field-directed therapy, paving the way for personalised care strategies.

This literature review highlights AI's promising role in acne detection, severity grading, and management, using advanced models like Convolutional Neural Networks. Despite impressive accuracy rates, real-world applications remain limited. Future efforts must focus on clinical validation, diverse populations, and standardized metrics to unlock AI's full potential in dermatology.

This pilot study showcases how AI-powered tools may improve diagnostic accuracy in dermatology within Primary Care. With a 12.96% overall improvement across various skin conditions, the study highlights AI's potential to support diagnoses, enhance professional training, and address key challenges in clinical practice.

Topical bimiralisib (PQR309), a dual PI3K/mTOR inhibitor, demonstrates high efficacy and excellent skin penetration in preclinical studies for actinic keratosis and cutaneous squamous cell carcinoma, offering a potentially promising new therapeutic approach.